Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data

European Journal of Health Economics

Volumn 16, Issue 7, 2015, Pages 709-717

  Gu, Yuanyuan ^a   García Pérez, Sonia ^b,c   Massie, John ^d,e,f   van Gool, Kees ^g  

^a MONASH UNIVERSITY   (Australia)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Red de Investigacion en Servicios de Salud en Enfermedades Cronicas REDISSEC Carlos III   (Spain)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^g UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Cost determinants; Cost of illness; Cystic fibrosis; Log transformation; Registry data

Indexed keywords

ADULT; AGE; ARTICLE; BACTERIAL INFECTION; COST BENEFIT ANALYSIS; COST CONTROL; COST OF ILLNESS; CYSTIC FIBROSIS; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; GENE MUTATION; HEALTH CARE COST; HUMAN; INFECTION; INFECTION RATE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; PRIORITY JOURNAL; REGISTER; AUSTRALIA; CHRONIC DISEASE; COMPLICATION; COMPUTER SIMULATION; ECONOMICS; GENETICS; HOSPITALIZATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; REGRESSION ANALYSIS; STAPHYLOCOCCUS INFECTION; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; AGE FACTORS; AUSTRALIA; BACTERIAL INFECTIONS; CHRONIC DISEASE; COMPUTER SIMULATION; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; REGISTRIES; REGRESSION ANALYSIS; STAPHYLOCOCCAL INFECTIONS; YOUNG ADULT;

EID: 84938963191     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-014-0621-5     Document Type: Article

References (36)

1. Cystic fibrosis in Australia: 12th annual report from the Australian cystic fibrosis data registry, p. 2009. Australia, Cystic Fibrosis Australia (2009)
2. AIHW. Health expenditure for arthritis and musculoskeletal conditions in Australia, 2000–01. Canberra: Australian Institute of Health and Welfare (2006)
3. Baumann, U., Stocklossa, C., Greiner, W., von der Schulenburg, J.M., von der Hardt, H.: Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2, 84–90 (2003)
4. Colagiuri, S., Colagiuri, R., Grainger, D., Graham-Clarke, P., Davey, P., Fitzgerald, P., Conway, B.: Diabcost Australia—assessing the burden of type 2 diabetes in Australia. Diabetologia 45, A300–A300 (2002)
5. Corey, M., Farewell, V.: Determinants of mortality from cystic fibrosis in Canada, 1970–1989. Am J Epidemiol 143, 1007–1017 (1996)
6. Dasenbrook, E.C., Checkley, W., Merlo, C.A., Konstan, M.W., Lechtzin, N., Boyle, M.P.: Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 303, 2386–2392 (2010)
7. Dewitt, E.M., Grussemeyer, C.A., Friedman, J.Y., Dinan, M.A., Lin, L., Schulman, K.A., Reed, S.D.: Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial. Value in health 15, 277–283 (2012)
8. Dodge, J.A., Morison, S., Lewis, P.A., Coles, E.C., Geddes, D., Russell, G., Littlewood, J.M., Scott, M.T.: Incidence, population, and survival of cystic fibrosis in the UK, 1968–95.UCFSM Committee. Arch Dis Child 77, 493–496 (1997)
9. Duan, N.: Smearing estimate—a nonparametric retransformation method. J Am Stat Assoc 78, 605–610 (1983)
10. Eidt-Koch, D., Wagner, T.O., Mittendorf, T., Graf von der Schulenburg, J.M.: Outpatient medication costs of patients with cystic fibrosis in Germany. Appl Health Econ Health Policy 8, 111–118 (2010)
11. Frangolias, D.D., Mahenthiralingam, E., Rae, S., Raboud, J.M., Davidson, A.G.F., Wittmann, R., Wilcox, P.G.: Burkholderia cepacia in cystic fibrosis—variable disease course. Am J Respir Crit Care Med 160, 1572–1577 (1999)
12. Heimeshoff, M., Hollmeyer, H., Schreyogg, J., Tiemann, O., Staab, D.: Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre. Pharmacoeconomics 30, 763–777 (2012)
13. Jacques, I., Derelle, J., Weber, M., Vidailhet, M.: Pulmonary evolution of cystic fibrosis patients colonized by Pseudomonas aeruginosa and/or Burkholderia cepacia. Eur J Pediatr 157, 427–431 (1998)
14. Johansen, H.K., Nir, M., Hoiby, N., Koch, C., Schwartz, M.: Severity of cystic-fibrosis in patients homozygous and heterozygous for delta-f508 mutation. Lancet 337, 631–634 (1991)
15. Johnson, J.A., Connolly, M.A., Jacobs, P., Montgomery, M., Brown, N.E., Zuberbuhler, P.: Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase. Pharmacotherapy 19, 1159–1166 (1999)
16. Jones, A.M.: Models for health care. In: Hendry, D., Clements, M. (eds.) Oxford handbook of economic forecasting, pp. 625–654. Oxford University Press, New York (2011)
17. Kerem, E., Corey, M., Gold, R., Levison, H.: Pulmonary-function and clinical course in patients with cystic-fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr. 116, 714–719 (1990)
18. Kerem, E., Reisman, J., Corey, M., Canny, G.J., Levison, H.: Prediction of mortality in patients with cystic-fibrosis. N Engl J Med 326, 1187–1191 (1992)
19. Krauth, C., Jalilvand, N., Welte, T., Busse, R.: Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics 21, 1001–1024 (2003)
20. Lieu, T.A., Ray, G.T., Farmer, G., Shay, G.F.: The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 103, art. no.e72 (1999)
21. Liou, T.G., Adler, F.R., FitzSimmons, S.C., Cahill, B.C., Hibbs, J.R., Marshall, B.C.: Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 153, 345–352 (2001)
22. Manning, W.G., Basu, A., Mullahy, J.: Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ 24, 465–488 (2005)
23. Massie, R.J., Olsen, M., Glazner, J., Robertson, C.F., Francis, I.: Newborn screening for cystic fibrosis in victoria: 10 years’ experience (1989-1998). Med J Aust 172, 584–587 (2000)
24. Mayer-Hamblett, N., Rosenfeld, M., Emerson, J., Goss, C.H., Aitken, M.L.: Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 166, 1550–1555 (2002)
25. O’Brien, R.M.: A caution regarding rules of thumb for variance inflation factors. Qual Quant 41, 673–690 (2007)
26. Ouyang, L., Grosse, S.D., Amendah, D.D., Schechter, M.S.: Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 44, 989–996 (2009)
27. Pamukcu, A., Bush, A., Buchdahl, R.: Effects of Pseudomonas aeruginosa colonization on lung-function and anthropometric variables in children with cystic fibrosis. Pediatr Pulonol 19, 10–15 (1995)
28. PBAC. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee Canberra. Department of Health and Ageing (2008)
29. Ramsey, B.W., Astley, S.J., Aitken, M.L., Burke, W., Colin, A.A., Dorkin, H.L., Eisenberg, J.D., Gibson, R.L., Harwood, I.R., Schidlow, D.V., Wilmott, R.W., Wohl, M.E., Meyerson, L.J., Shak, S., Fuchs, H., Smith, A.L.: Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 148, 145–151 (1993)
30. Schreyogg, J., Hollmeyer, H., Bluemel, M., Staab, D., Busse, R.: Hospitalisation costs of cystic fibrosis. Pharmacoeconomics 24, 999–1009 (2006)
31. Serginson, J.G., Yang, I.A., Armstrong, J.G., Cooper, D.M., Matthiesson, A.M., Morrison, S.C., Gair, J.M., Cooper, B., Zimmerman, P.V.: Variability in the rate of prescription and cost of domiciliary oxygen therapy in Australia. Med J Aust 191, 549–553 (2009)
32. Singh, S.J., Sodergren, S.C., Hyland, M.E., Williams, J., Morgan, M.D.: A comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD. Respir Med 95, 71–77 (2001)
33. Stallings, V.A., Stark, L.J., Robinson, K.A., Feranchak, A.P., Quinton, H., Group, AHW: Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 108, 832–839 (2008)
34. van Gool, K., Norman, R., Delatycki, M.B., Hall, J., Massie, J.: Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value in health 16, 345–355 (2013)
35. Welsh, M., Ramsey, B., Accurso, F., Cutting, G.: Cystic fibrosis. In: Scriver, C., Beaudet, A., Sly, W., Valle, D. (eds.) The metabolic and molecular bases of inherited disease, pp. 5121–5188. McGraw-Hill, New York (2001)
36. White, H.: A heteroskedasticity-consistent covariance-matrix estimator and a direct test for heteroskedasticity. Econometrica 48, 817–838 (1980)